Can insurance claims replace clinical trials? researchers put semaglutide to the test

NCT ID NCT06914102

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at healthcare claims data from over 58,000 people to see if it could reproduce the results of the STEP-HFpEF DM trial, which tested semaglutide for heart failure with preserved ejection fraction in people with type 2 diabetes. Researchers compared new users of semaglutide to those starting sitagliptin (as a placebo proxy). The goal was to learn whether real-world data can reliably answer clinical questions, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Semaglutide
What this could lead to
If successful, this could show that analyzing real-world data can reliably predict trial outcomes, potentially speeding up research.
What could go wrong
This is an observational study using claims data, not a new treatment test. Results may not match the original trial due to data limitations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.